Tevogen Bio Holdings Inc.
TVGN
$0.9922
-$0.0178-1.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 427.74% | 232.07% | 152.11% | 69.00% | -47.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 505.72% | 365.70% | 266.09% | 183.08% | -35.56% |
| Operating Income | -505.72% | -365.70% | -266.09% | -183.08% | 35.56% |
| Income Before Tax | 77.30% | 87.35% | 90.66% | 60.80% | -174.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 77.30% | 87.35% | 90.66% | 60.80% | -174.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 77.30% | 87.35% | 90.66% | 60.80% | -174.38% |
| EBIT | -505.72% | -365.70% | -266.09% | -183.08% | 35.56% |
| EBITDA | -515.26% | -372.36% | -269.04% | -184.34% | 36.34% |
| EPS Basic | 86.17% | 79.53% | 83.60% | 68.24% | 28.93% |
| Normalized Basic EPS | -153.84% | -104.82% | -14.25% | 23.88% | 72.71% |
| EPS Diluted | 86.07% | 79.45% | 83.54% | 68.24% | 28.93% |
| Normalized Diluted EPS | -153.84% | -104.82% | -14.25% | 23.88% | 72.71% |
| Average Basic Shares Outstanding | 47.72% | 26.42% | 50.48% | 105.71% | 280.89% |
| Average Diluted Shares Outstanding | 47.72% | 26.42% | 50.48% | 105.71% | 280.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |